Nivolumab is an immune checkpoint inhibitor that targets the programmed death-1 (PD-1) pathway. By blocking this pathway, nivolumab enhances the immune system's ability to recognize and destroy cancer cells. This mechanism represents a shift from traditional therapies that directly target the tumor to approaches that empower the body's immune response.
